Frequency Therapeutics (FREQ) Reports Topline Phase 2b Data for FX-322 Feb 13, 2023 08:05AM
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss Feb 13, 2023 08:05AM